MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $131.01M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.57M
Average 0.98M
MGNX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
MacroGenics, Inc.NASDAQ: MGNX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$30.2M, compared with -$39.17M a year earlier. Trailing-twelve-month EBITDA was -$50.64M.
Context
- EBITDA amounted to 39.9% of revenue in FY2025, up 1.2 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$105.61M (-77.2%) for the fiscal year ending Dec 2026, a slowdown from the -3.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$30.2M-237.2% QoQ
- Last fiscal yearDec 2025
- -$59.61M-3.9% YoY
- LTMMar 2026
- -$50.64M-7.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +22.9% | +100.4% | +77.5 pp |
| 1 year | -3.9% | -77.2% | -73.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (59.61M) USD
- Year-over-year change
- -3.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59.61M) | -3.9% |
| FY2024 | 2024-12-31 | (57.37M) | -2944.2% |
| FY2023 | 2023-12-31 | 2.02M | +101.9% |
| FY2022 | 2022-12-31 | (107.89M) | +43.5% |
| FY2021 | 2021-12-31 | (190.86M) | — |
EBITDA vs competitors
How MGNX compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.0% is the 6th highest of 11, against a peer median of -8.4%.
- EBITDA amounts to 32.2% of revenue for MGNX, versus a peer median of 13207.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $78.84M USD | +1391.3% | — | — | |
| LTM Mar 2026 | -$21.1M USD | -18.3% | — | 265.8% | |
| LTM Mar 2026 | -$24M USD | +7.8% | — | 337.0% | |
| LTM Mar 2026 | -$29.2M USD | -21.6% | — | 21792.5% | |
| LTM Mar 2026 | -$40.18M USD | -45.5% | — | — | |
| LTM Mar 2026 | -€42.36M EUR | +1.6% | — | 144435.8% | |
| LTM Mar 2026 | -$46.23M USD | +30.8% | — | 4623.1% | |
| LTM Mar 2026 | -$50.64M USD | -7.0% | — | 32.2% | |
| FY2025 | -$54.58M USD | -270.2% | — | 85279.7% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | -$115.78M USD | -490.7% | — | — |
| LTM Mar 2026 | -$130.98M USD | +37.9% | — | — | |
| Peer median (excluding MGNX) | — | -8.4% | — | 13207.8% | |
Competitors are the stored peer set for MGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 75.64M | 150.02M | 57.19M | 148.34M | 149.5M |
| Cost of Revenue | 2.65M | 7.38M | 8.22M | 12.3M | 43.18M |
| Gross Profit | 72.99M | 142.63M | 48.97M | 136.04M | 106.32M |
| Gross Margin | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| Research & Development | 214.58M | 207.03M | 166.58M | 177.19M | 140M |
| Selling, General & Admin | 63.01M | 58.95M | 52.19M | 71.05M | 39.16M |
| Operating Expenses | 275.79M | 264.05M | 217.22M | 246.62M | 179.16M |
| Depreciation & Amortization | 11.26M | 11.87M | 9.65M | 7.54M | 7.17M |
| EBITDA | (190.86M) | (107.89M) | 2.02M | (57.37M) | (59.61M) |
| EBITDA Margin | -252.3% | -71.9% | 3.5% | -38.7% | -39.9% |
| Operating Income | (202.8M) | (121.42M) | (168.24M) | (110.58M) | (72.84M) |
| Operating Margin | -268.1% | -80.9% | -294.2% | -74.5% | -48.7% |
| Interest Income | 680K | 1.7M | 9.69M | 9.42M | 3.4M |
| Interest Expense | 0 | 0 | 1.43M | 1.12M | 8.51M |
| Other Income / Expenses | 680K | 1.66M | 159.19M | 44.56M | (2.45M) |
| Income Before Tax | (202.12M) | (119.76M) | (9.06M) | (66.02M) | (75.29M) |
| Pre-Tax Margin | -267.2% | -79.8% | -15.8% | -44.5% | -50.4% |
| Income Tax Expense | 0 | 0 | 0 | 944K | (672K) |
| Net Income | (202.12M) | (119.76M) | (9.06M) | (66.97M) | (74.62M) |
| Net Margin | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (Basic) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| EPS (Diluted) | (3.18) | (1.95) | (0.15) | (1.07) | (1.18) |
| Weighted Avg Shares | 59.94M | 61.41M | 61.93M | 62.62M | 63.16M |
| Weighted Avg Shares (Diluted) | 59.94M | 61.43M | 61.93M | 62.62M | 63.16M |
MacroGenics, Inc.
NASDAQ:MGNX
Intrinsic Alpha fair value
Locked
Current Price
$2.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.